The NIH's National Institute on Aging awarded Oligomerix a two-year, $1.7 million grant to support its research on small molecule drugs designed to prevent tau oligomer formation, which is believed to play a key role in Alzheimer's disease progression. "This program will allow us to evaluate our lead candidates in animal models of AD and related tauopathies with the goal of selecting candidates for IND enabling studies, a prelude to initial clinical evaluation," Oligomerix President and CEO James Moe said.

Related Summaries